Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.

Smith J, Robida MD, Acosta K, Vennapusa B, Mistry A, Martin G, Yates A, Hnatyszyn HJ.

Diagn Pathol. 2016 May 18;11(1):44. doi: 10.1186/s13000-016-0494-2.

2.

Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor.

Iorns E, Ward TM, Dean S, Jegg A, Thomas D, Murugaesu N, Sims D, Mitsopoulos C, Fenwick K, Kozarewa I, Naceur-Lombarelli C, Zvelebil M, Isacke CM, Lord CJ, Ashworth A, Hnatyszyn HJ, Pegram M, Lippman M.

Breast Cancer Res Treat. 2012 Aug;135(1):79-91. doi: 10.1007/s10549-012-2068-7. Epub 2012 Apr 26.

PMID:
22535017
3.

The role of SATB1 in breast cancer pathogenesis.

Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M.

J Natl Cancer Inst. 2010 Aug 18;102(16):1284-96. doi: 10.1093/jnci/djq243. Epub 2010 Jul 1.

PMID:
20595686
4.

Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody.

Hnatyszyn HJ, Liu M, Hilger A, Herbert L, Gomez-Fernandez CR, Jorda M, Thomas D, Rae JM, El-Ashry D, Lippman ME.

Breast Cancer Res Treat. 2010 Jul;122(2):371-80. doi: 10.1007/s10549-009-0584-x. Epub 2009 Oct 20.

PMID:
19842031
5.

Chronic hepatitis B and viral genotype: the clinical significance of determining HBV genotypes.

Guettouche T, Hnatyszyn HJ.

Antivir Ther. 2005;10(5):593-604. Review.

PMID:
16152753
6.
7.

Multicenter evaluation of the VERSANT hepatitis B virus DNA 3.0 assay.

Yao JD, Beld MG, Oon LL, Sherlock CH, Germer J, Menting S, Se Thoe SY, Merrick L, Ziermann R, Surtihadi J, Hnatyszyn HJ.

J Clin Microbiol. 2004 Feb;42(2):800-6.

9.

Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences.

Kraus G, Geffin R, Spruill G, Young AK, Seivright R, Cardona D, Burzawa J, Hnatyszyn HJ.

Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3406-11.

10.

Rapid and specific detection of the Mycobacterium tuberculosis complex using fluorogenic probes andreal-time PCR.

Kraus G, Cleary T, Miller N, Seivright R, Young AK, Spruill G, Hnatyszyn HJ.

Mol Cell Probes. 2001 Dec;15(6):375-83.

PMID:
11851381
11.

The use of real-time PCR and fluorogenic probes for rapid and accurate genotyping of newborn mice.

Hnatyszyn HJ, Podack ER, Young AK, Seivright R, Spruill G, Kraus G.

Mol Cell Probes. 2001 Jun;15(3):169-75.

PMID:
11352598
12.

Potent inhibition of CTLA-4 expression by an anti-CTLA-4 ribozyme.

Cepero E, Hnatyszyn HJ, Kraus G, Lichtenheld MG.

Biochem Biophys Res Commun. 1998 Jun 29;247(3):838-43.

PMID:
9647780
13.

Surface-modified diamond nanoparticles as antigen delivery vehicles.

Kossovsky N, Gelman A, Hnatyszyn HJ, Rajguru S, Garrell RL, Torbati S, Freitas SS, Chow GM.

Bioconjug Chem. 1995 Sep-Oct;6(5):507-11.

PMID:
8974446
14.

Surface-modified nanocrystalline ceramics for drug delivery applications.

Kossovsky N, Gelman A, Sponsler EE, Hnatyszyn HJ, Rajguru S, Torres M, Pham M, Crowder J, Zemanovich J, Chung A, et al.

Biomaterials. 1994 Dec;15(15):1201-7.

PMID:
7703315
15.

Drug delivery systems for the future.

Hnatyszyn HJ, Kossovsky N, Gelman A, Sponsler E.

PDA J Pharm Sci Technol. 1994 Sep-Oct;48(5):247-54. Review.

PMID:
8000899

Supplemental Content

Loading ...
Support Center